MOUD stands for Medications for Opioid Use Disorder. It refers to the three FDA-approved medications used to treat opioid addiction: buprenorphine, methadone, and naltrexone. You may also see the older term MAT (Medication-Assisted Treatment), but the field has been moving away from that language for an important reason.
Why the Name Changed From MAT to MOUD
For years, the standard term was Medication-Assisted Treatment. The problem with that phrase is the word “assisted,” which implies that medication plays a supporting role to counseling rather than being a primary treatment in its own right. As SAMHSA has noted, the term MAT “has been criticized as implying that the medications are not as important as counseling” and that it further stigmatizes medications like methadone and buprenorphine. The shift to MOUD recognizes that these medications are effective, evidence-based treatments on their own, not just add-ons to therapy.
The Three MOUD Medications
Each of the three approved medications works differently in the brain, and they’re used in different situations depending on a person’s needs and circumstances.
Methadone
Methadone activates the same brain receptors that opioids do, but in a slow, controlled way that prevents withdrawal symptoms and cravings without producing a high. It has the longest track record of the three medications. In a study following people after an opioid overdose, those receiving methadone had a 59% reduction in overdose deaths over the following year compared to those not on medication. Among young adults with opioid use disorder, median treatment retention on methadone was 324 days, far longer than the 67 days seen with behavioral therapy alone.
Methadone is typically dispensed daily at specialized opioid treatment programs, where a nurse or pharmacist administers the dose on-site. Patients who demonstrate stability over time can earn take-home doses, reducing the number of clinic visits.
Buprenorphine
Buprenorphine partially activates opioid receptors, enough to ease withdrawal and cravings but with a built-in ceiling effect that makes overdose much less likely. It’s the most widely prescribed MOUD because it can be prescribed in a regular doctor’s office and filled at a retail pharmacy, making it far more accessible than methadone. Common formulations include sublingual films and tablets (some combined with naloxone to discourage misuse) and monthly injections.
In the same post-overdose study, buprenorphine was associated with a 38% reduction in overdose deaths. Median retention among young adults was 123 days, roughly double the retention seen with counseling alone.
Naltrexone
Naltrexone works completely differently from the other two. Instead of activating opioid receptors, it blocks them entirely. If someone taking naltrexone uses opioids, they won’t feel the effects. It’s available as a daily pill or a monthly injection. Because it blocks opioid receptors, a person needs to be fully detoxed from opioids before starting it, which can be a barrier for some people. It can also be prescribed by any healthcare provider with standard prescribing authority.
How MOUD Works in the Brain
Opioid addiction physically reshapes brain circuits involved in reward, motivation, and decision-making. Over time, the brain becomes dependent on opioids to function normally, which is why willpower alone rarely works as a long-term solution. MOUD medications restore balance to these disrupted circuits. They prevent withdrawal, reduce cravings, and allow the brain’s decision-making functions to recover. The American Psychiatric Association emphasizes that these medications do not cause a high. They stabilize brain chemistry so people can return to normal life and regain control over their choices.
Prescribing Access Has Expanded
Until recently, doctors needed a special federal waiver (called an X-waiver) to prescribe buprenorphine, and they were limited in how many patients they could treat. That changed in 2023, when Congress eliminated the waiver requirement entirely. Now, any practitioner with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder, with no cap on the number of patients. New or renewing DEA registrants do need to complete at least eight hours of training on substance use disorders, or hold board certification in addiction medicine or addiction psychiatry.
This was a significant shift. The old waiver system meant that even willing doctors often couldn’t treat addiction, leaving patients on long waiting lists. The removal of these barriers has opened the door for primary care doctors, nurse practitioners, and physician assistants to offer buprenorphine alongside their regular practice. State laws still apply, so access varies somewhat by location.
How Long Treatment Lasts
There is no recommended time limit for buprenorphine or naltrexone treatment, according to guidelines from the American Society of Addiction Medicine. Duration depends on clinical judgment and individual circumstances. Some people stay on MOUD for years, and that’s considered appropriate care, not a failure. Stopping too early is one of the most common reasons for relapse.
If someone does taper off buprenorphine, the process is generally slow, stretching over several months with close monitoring. The gradual approach gives the brain time to readjust without triggering a return of intense cravings.
MOUD During Pregnancy
Both methadone and buprenorphine are recommended as first-line treatments for pregnant people with opioid use disorder. Untreated opioid addiction during pregnancy carries serious risks, including preterm birth, low birth weight, and stillbirth. MOUD significantly reduces those risks. Newborns exposed to these medications may experience neonatal abstinence syndrome (temporary withdrawal symptoms after birth), but this is an expected, treatable condition. The CDC and the American College of Obstetricians and Gynecologists agree that concern about neonatal withdrawal alone should not prevent providers from prescribing MOUD during pregnancy. Naltrexone is not currently recommended during pregnancy.